Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer

Novocure Ltd NVCR has entered into a clinical trial collaboration agreement with Roche Holdings AG RHHBY to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC).
The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as a first-line treatment for mPDAC.
The study will enroll approximately 75 patients with a primary endpoint of disease control rate.
The secondary endpoints include overall survival, progression-free survival (PFS), one-year survival, objective response rate, PFS at six months, duration of response, and toxicity profile.
Novocure is the study sponsor, and Roche is providing atezolizumab for the trial.
Related: Novocure Presents Final Safety and Efficacy Results From Liver Cancer Trial.
Tumor Treating Fields are electric fields that disrupt cancer cell division.
Last week, the FDA granted breakthrough designation to the NovoTTF-200T System, TTFields, to be delivered together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer.
Price Action: NVCR stock closed 1.74% lower at $129.53, while RHHBY closed at $46.31 on Monday.